Should I buy these 2 penny stocks?

News coming out of these low-cost UK shares has been encouraging in recent months. Is now the time for me to buy these penny stocks?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The news flow coming out of penny stock Petra Diamonds (LSE: PDL) of late has been far more positive than it was a year ago. But, then again, things couldn’t have been much worse. The diamond digger even put itself up for sale last summer because of its severe financial troubles.

There’s been a glimmer of light for the penny stock in more recent months. Precious stones prices have risen again as the economic recovery from 2020’s lows has kicked in. Fresh fundraising earlier this year, allied with an improvement on the production front, has also raised optimism over Petra Diamonds’ long-term future.

I’m still yet to be convinced to buy this stock however. I’m not just worried about how the recent resurgence of Covid-19 cases could impact the diamond market again. And especially what this would mean for Petra Diamonds, given that its balance sheet is still looking petty fragile. The patchy long-term outlook for the natural diamond market also gives me reason to be concerned.

Demand for lab-grown stones has been steadily increasing in recent years. And researchers at Statista expect the market to explode over the next decade. They reckon market volumes will stand at 19.2m carats in 2030. That compares with 6.2m last year and 1m carats in 2010.

It’s also possible that investor interest in Petra Diamonds’ shares will fall as the importance of responsible investing grows. Concerns over worker conditions in South African mines has, along with price, driven the popularity boom for artificial stones. These rising ethical concerns are something that could also drag the Petra Diamonds share price lower over the next decade. Today, the company trades at 1.7p per share.  

A better penny stock to buy

I’d much rather buy UK healthcare share Shield Therapeutics (LSE: STX) for my shares portfolio. This penny stock trades at 45p per share, and I think it could soar in value as the problem of iron deficiency explodes.

Shield Therapeutics’ leading product is Feraccru/Accrufer, a treatment for iron deficiency anaemia. Sales of the drug are rocketing in Europe, with volumes ballooning 51% in the first half of 2021 versus the final six months of last year.

Encouragingly, the pharma firm launched the product in the US on 1 July after getting regulatory approval there. And China has potentially opened the door to the drug being released in that gigantic growth market too, having recently received approved of a new drug application for Feraccru.

Remember that regulatory approval is, of course, by no means guaranteed in China (as is the case elsewhere). Thus, all the hard work Shield Therapeutics has carried out could fail to meet expectations. Still, I’m encouraged by the thumbs ups the penny stock’s product has received from European and American regulators.

I think the company’s work to treat a major global health problem could reap huge rewards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »